Any feedback?
Literature summary for 3.4.15.1 extracted from
- Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controled trials (2008), J. Card. Fail., 14, 181-188.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | patients with left ventricular dysfunction have an increased risk of adverse events leading to discontinuation on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker combination therapy compared with angiotensin-converting enzyme inhibitor alone. This excess risk, coupled with a lack of consistent mortality benefit, suggests that angiotensin receptor blocker should not routinely be added to angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
